Claudication of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Disease : A Phase II Randomized , Double-Blind , Controlled Study of Adenoviral Delivery Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial
暂无分享,去创建一个
Brian H Annex | Sanjay Rajagopalan | Robert J Lederman | John Blebea | Emile R Mohler | S. Rajagopalan | R. Lederman | E. Mohler | P. Kessler | J. Blebea | B. Annex | F. Mendelsohn | J. Saucedo | Farrell O Mendelsohn | Jorge F Saucedo | Corey K Goldman | Jennifer Macko | Paul D Kessler | Henrik S Rasmussen | H. Rasmussen | C. Goldman | J. Macko
[1] Photocoagulation therapy for diabetic eye disease. Early Treatment Diabetic Retinopathy Study Research Group. , 1985, JAMA.
[2] P. Carmeliet,et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.
[3] I. Kovesdi,et al. Increased revascularization efficacy after administration of an adenovirus encoding VEGF121 , 2004, Gene Therapy.
[4] R O Bonow,et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.
[5] J. Bergelson,et al. The Murine CAR Homolog Is a Receptor for Coxsackie B Viruses and Adenoviruses , 1998, Journal of Virology.
[6] J. A. Herd,et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. , 1998, Journal of vascular surgery.
[7] J. Isner,et al. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.
[8] L. Philipson,et al. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[9] P. Kligfield,et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. , 1999, Annals of surgery.
[10] S. Rajagopalan,et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. , 2002, The American journal of cardiology.
[11] S. Rajagopalan,et al. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. , 2003, American heart journal.
[12] R. Lederman,et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.
[13] M. Post,et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.
[14] Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.
[15] Hanns Lochmüller,et al. Strategies for muscle-specific targeting of adenoviral gene transfer vectors , 2002, Neuromuscular Disorders.
[16] R. Crystal,et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. , 1998, Journal of vascular surgery.
[17] E. Lakatta,et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. , 2000, Circulation.
[18] J. Skinner,et al. Progressive vs single-stage treadmill tests for evaluation of claudication. , 1991, Medicine and science in sports and exercise.
[19] C. Diehm,et al. European multicenter study on propionyl-L-carnitine in intermittent claudication. , 1999, Journal of the American College of Cardiology.
[20] D. Dawson,et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. , 1998, Circulation.
[21] Hanns Lochmüller,et al. The spread of transgene expression at the site of gene construct injection , 2001, Muscle & nerve.
[22] K. Alitalo,et al. Gene transfer as a tool to induce therapeutic vascular growth , 2003, Nature Medicine.
[23] Brian H Annex,et al. The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .
[24] R. Hajjar,et al. Decreased Efficiency of Adenovirus-Mediated Gene Transfer in Aging Cardiomyocytes , 2003, Circulation.
[25] S. Rajagopalan,et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial , 2003, Vascular medicine.
[26] Peter Carmeliet,et al. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.